Pack	Code	Status
VYDURA 75 MG LIOFILIZADO ORAL, 8 comprimidos	750418
VYDURA 75 MG LIOFILIZADO ORAL, 16 comprimidos	763545
VYDURA 75 MG LIOFILIZADO ORAL, 2 comprimidos	764490

Documents

The official texts, at the regulator.

Sources and licences

Compiled by Prognia from the public register below; the register’s text is the official one.

Agencia Española de Medicamentos y Productos Sanitarios

Fuente de la información: Agencia Española de Medicamentos y Productos Sanitarios www.aemps.gob.es; CIMA medicamentos, acquired 11 October 2026 UTC; each source response/update date retained.

Licence: AEMPS explicit public open-data reuse for citizens and companies; source attribution and update date required · Added 12 Oct 2026

Report an error or request removalCorrections from the holder or the register are welcome.

Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.

At a glance

Active substance: Rimegepant
Strength: 85,65 mg
Dosage form: liofilizado oral
Route: vía oral
Register: Spain (AEMPS)
Status: Marketed
Status in the register: Autorizado, comercializado
Authorised: 6 Jun 2022
Registration: 1221645002
Marketing authorisation holder: Pfizer Europe Ma Eeig
Procedure: EU centralised
Supply: Medicamento Sujeto A Prescripción Médica
EU number: EU/1/22/1645